The group has appointed Delta Matrix as its exclusive manufacturer and wholesaler, bringing USB power modules based on its OSMIUM technology to market for the first time.

Frontier IP's portfolio company secures non-dilutive European funding and shifts strategic focus toward industrial pharmaceutical inspection, a market seen tripling in size by 2033.

"This funding allows us to take a significant step towards that goal by bringing our proprietary algorithms beyond specialised clinical settings and into everyday wearable devices," said inSignals co-founder and chief science officer João Paulo Cunha.

"This fundraising will support Frontier IP in delivering on the significant value we see in our maturing portfolio," said Crabb, adding that the company was pleased to receive backing from both existing and new investors.

Frontier IP Group has launched a proposed placing and subscription to raise minimum gross proceeds of £4.0 million, split between a £3.88m placing and a £0.12m subscription.